MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-08-2022
Turning Point Therapeutics Retained Earnings 2011-2026 | TPTX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Turning Point Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -517 M | -280 M | -123 M | -50.8 M | -26 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -26 M | -517 M | -199 M |
Quarterly Retained Earnings Turning Point Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -714 M | -591 M | -517 M | -438 M | -372 M | -316 M | -280 M | -280 M | -280 M | -280 M | -123 M | -123 M | -123 M | -123 M | -50.8 M | -50.8 M | -50.8 M | -50.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -50.8 M | -714 M | -265 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-351 M | - | 10.36 % | $ 9.8 M | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 215.54 | -1.16 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
-353 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
-447 M | $ 3.88 | -1.27 % | $ 415 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
667 M | $ 19.23 | - | $ 899 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-555 M | $ 8.18 | -2.97 % | $ 109 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Atreca
BCEL
|
-457 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
-8.32 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-4.26 B | - | - | $ 546 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Cara Therapeutics
CARA
|
-685 M | - | -3.03 % | $ 260 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-113 M | $ 0.71 | 17.15 % | $ 8.13 M | Israel |
 |
Avenue Therapeutics
ATXI
|
-103 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.1 B | $ 1.32 | -5.71 % | $ 337 M | Britain |
 |
CytomX Therapeutics
CTMX
|
-712 M | $ 4.24 | -4.83 % | $ 585 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-439 M | - | -5.98 % | $ 34.1 M | USA |
 |
ChemoCentryx
CCXI
|
-617 M | - | - | $ 3.74 B | USA |
 |
Genmab A/S
GMAB
|
7.11 B | $ 25.81 | 0.51 % | $ 16.6 B | Danmark |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.65 | 0.76 % | $ 16.6 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-903 M | - | - | $ 2.02 B | USA |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |
 |
Enochian Biosciences
ENOB
|
-510 M | - | - | $ 40.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Eton Pharmaceuticals
ETON
|
-112 M | $ 22.97 | -3.53 % | $ 618 M | USA |
 |
Exelixis
EXEL
|
-76.8 M | $ 41.57 | 0.39 % | $ 11.3 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-252 M | - | -74.18 % | $ 955 K | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Fortress Biotech
FBIO
|
-741 M | $ 2.92 | -2.01 % | $ 60.7 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-1.38 B | $ 4.31 | -2.49 % | $ 826 M | Canada |
 |
Homology Medicines
FIXX
|
-205 M | - | 0.77 % | $ 53.4 M | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |